Adocia , a biotechnology company specialized in the development of best-in-class medicines with already-approved therapeutic proteins, announces that the USPTO and the EPO have issued a patent covering BioChaperone PDGF formulations for chronic wound treatment, including diabetic foot ulcer, to Adocia.
This patent covers the innovative formulation of PDGF with a polymer of the platform BioChaperone(R), property of Adocia. This polymer has been designed by Adocia to form a molecular complex with this specific growth factor. Thanks to this technology, PDGF is protected from enzymatic degradation enabling a reduction of the PDGF dose by a factor of three and also the frequency of administration, from once-a-day to once-every-two days. These significant therapeutic advantages have been confirmed by the positive results of the phase II clinical trial in India, published in a press release on April 23, 2012. Phase III clinical trials are in preparation and the first study could be initiated before year-end in India.
“The issuance of these patents by American and European agencies validates the BioChaperone technology in terms of novelty and innovation,” said Olivier Soula, VP, R&D director and cofounder of Adocia.
“We have the confirmation of the intellectual protection of our product for the treatment of chronic wounds for the next fifteen years,” said Gérard Soula, president CEO and cofounder of Adocia. “This is a key element for licensing our product to pharmaceutical companies.”
About Adocia
“Innovative medicine for everyone, everywhere”
Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.
Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51 per cent increase, reaching 70 per cent in emerging countries). 15 per cent of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD 20 billion (USD 17 billion for insulin therapy and USD three billion for diabetic foot ulcer healing).
Through its BioChaperone(R) state-of-the-art technological platform, Adocia enhances the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.
Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer healing product. Adocia also confirmed the value of its technology for the formulation of a fast-acting insulin analog by signing an exclusive worldwide license agreement with a major pharmaceutical company. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.
To be a global leader for the formulation of therapeutic proteins
Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.
Adocia’s therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.
Adocia is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg : ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index.For more information: http://www.adocia.com
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the “Risk Factors” sections of the prospectus registered by the Autorité des marchés financiers on January 25, 2012 under number 12-034 (a copy of which is available on http://www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Adocia shares in any country.
